Page last updated: 2024-12-09

1-(2-tert-butylphenyl)-3-cyclohexylthiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(2-tert-butylphenyl)-3-cyclohexylthiourea, often abbreviated as **(2-tBuPh)CHThiourea**, is a specific type of organic compound known as a thiourea. It's a **potential drug candidate** and its importance stems from its promising biological activities.

Here's a breakdown:

* **Structure:** The molecule consists of a thiourea core, which is a sulfur analog of urea. Attached to the thiourea are:
* **2-tert-butylphenyl:** This bulky group provides steric hindrance (spatial crowding) which can influence the way the molecule interacts with other molecules.
* **Cyclohexyl:** This cyclic alkyl group contributes to the molecule's overall hydrophobic (water-repelling) nature.

* **Biological Activities:** (2-tBuPh)CHThiourea has been researched for its potential in various areas:
* **Antioxidant Activity:** Thioureas have been shown to exhibit antioxidant properties, protecting cells against damaging free radicals.
* **Anticancer Activity:** Some thioureas have shown promise as anticancer agents, potentially by interfering with tumor cell growth and survival.
* **Anti-inflammatory Activity:** Thioureas may be able to reduce inflammation by modulating the activity of inflammatory mediators.
* **Neuroprotective Activity:** There is some research suggesting that certain thioureas might be neuroprotective, meaning they could protect neurons from damage.

* **Research Importance:** (2-tBuPh)CHThiourea is significant because it represents a promising starting point for the development of new drugs with therapeutic potential. Researchers are exploring its structure-activity relationships to understand how modifications to the molecule might affect its biological properties.

**Key Points to Remember:**

* This compound is still under investigation and is not yet approved for any medical uses.
* The exact mechanisms by which (2-tBuPh)CHThiourea exerts its effects are not fully understood and require further research.
* Its importance lies in its potential as a lead compound for the development of new drugs for a variety of diseases.

If you're interested in learning more, I suggest searching for research articles specifically on 1-(2-tert-butylphenyl)-3-cyclohexylthiourea or similar thiourea derivatives. You can use databases like PubMed or Google Scholar to find relevant publications.

Cross-References

ID SourceID
PubMed CID2349790
CHEMBL ID1419309
CHEBI ID109216

Synonyms (12)

Synonym
OPREA1_613888
smr000352495
MLS001007301
CHEBI:109216
AKOS000970838
1-(2-tert-butylphenyl)-3-cyclohexylthiourea
HMS2707F22
CHEMBL1419309
Q27188291
Z45831544
380337-10-0
DTXSID801333612
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency4.46680.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency17.78280.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency3.98110.100022.9075100.0000AID485364
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency4.04390.00798.23321,122.0200AID2546; AID2551
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency25.11890.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency0.04470.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]